PeterJEngelMD

Cardiology • Cincinnati, OH

Adult Congenital Heart Disease

Physician

Join to view full profile

Dr. Engel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Engel's full profile

Already have an account?

Office
2123 Auburn Ave
Ste 137
Cincinnati, OH 45219
Phone+1 513-206-1180

Fax+1 513-206-1183

Education & Training

University of Cincinnati Medical Center/College of MedicineFellowship, Cardiovascular Disease, 1975 - 1976
University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 1971 - 1975
New York University School of MedicineClass of 1971

Certifications & Licensure

OH State Medical License 1973 - 2027
KY State Medical License 1978 - 2026
IN State Medical License 1980 - 2023
CA State Medical License 2002 - 2021
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)
COMPLETED
PHASE4
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension Start of enrollment: 2009 Dec 01
COMPLETED
PHASE3
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl. Start of enrollment: 2011 Mar 01
Completed
Phase 2
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program Start of enrollment: 2011 Jun 01
Completed
Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH) Start of enrollment: 2011 Nov 01
Unknown status
Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument Start of enrollment: 2013 Apr 01
Completed
Phase 3
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT Start of enrollment: 2014 May 31
Completed
Phase 2
Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE Start of enrollment: 2017 Feb 03
Completed
Phase 2, Phase 3
Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER Start of enrollment: 2017 Apr 18
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

8 citations
Echocardiographic estimate of pulmonary artery pressure in sarcoidosis patients - real world data from a multi-national study.
Marloes P Huitema, Marco C Post, Jan C Grutters, Athol U Wells, Vasilis Kouranos
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases. 2022-01-01
26 citations
Riociguat for Sarcoidosis-Associated Pulmonary Hypertension: Results of a 1-Year Double-Blind, Placebo-Controlled Trial.
Robert P. Baughman, Oksana A. Shlobin, Rohit Gupta, Peter J. Engel, Jeffrey I. Stewart
Chest. 2021-08-04
265 citations
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
Aaron B. Waxman, Ricardo Restrepo-Jaramillo, Thenappan Thenappan, Ashwin Ravichandran, Peter A. Engel
The New England Journal of Medicine. 2021-01-28